Publications

Roy S, Armstrong AJ, Agarwal N, McKay RR, Jia AY, Lichtman-Mikol S, Barata PC, Garcia JA, Brown JR, Mumgandi Y, Basourakos SP, Sheng IY, Kishan AU, Zaorsky NG, Shoag JE, Morgan SC, Wallis CJD, Sun Y, Small EJ, Saad F, Shore ND, Spratt DE. External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial. Cancer. 2026. PMID: 42791604

Ang KK, Lipof J, Kumar A, Mikkilineni L, Chung A, Arora S, Sayre P, Wolf J, Chari A, Martin T, Pan D. Managing Novel CAR T-Cell Toxicities in Multiple Myeloma. Cancer journal (Sudbury, Mass.). 2026. PMID: 42809699

Yarchoan M, Llovet JM, Kelley RK, Finn R, Parikh ND, Tabrizian P, Burgoyne AM, Agopian VG, Sanford NN, Tran Cao HS, Padia SA, Vogel A, Lewandowski RJ, Kirema GR, Lin R, Mehta N, Sapisochin G, Yopp A, Villanueva A, Halazun K, Pinato DJ, Kim E, Heimbach JK, Pillai A, Salem R, El-Khoueiry A, Singal AG. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026. PMID: 42785981

Desai P, Pawlowska N, Mileti CJ, Worley DR, Wheeler R, Rairkar M, Thomas S, Munster PN. Development of prostate-selective, sustained-release anti-androgen implants for prostate cancer treatment. International journal of pharmaceutics. 2026. PMID: 42772704

Neely J, Yao J, Kudo M, Finn RS, Sangro B, Melero I, El-Khoueiry AB, Yau T, Harding JJ, Rosmorduc O, Tschaika M, Novosiadly R, Cruz A, Kelley RK. Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. JHEP reports : innovation in hepatology. 2026. PMID: 42762856

Licata L, Mariani M, Chiavassa A, Partridge AH, Zanibelli C, Jhaveri K, Kalinsky K, Patanè F, Criscitiello C, Lambertini M, Rugo HS, Naldini MM, Notini G, Viale G, Pusztai L, Bianchini G. Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2026. PMID: 42754095

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin Y, Ko M, Sayar E, Patton RD, Kollath L, Meis A, Lindergren S, Ji N, Ali K, Venkatesh H, Wladyka CL, McDeed AP, Mills CB, Vashisth M, Kim JY, Nadal R, Hawley JE, Yezefski TA, Psutka SP, Gore JL, Lin DW, Nelson PS, Cheng HH, Schweizer MT, Fong L, Lee JK, Yu EY, Corey E, Morrissey C, Grivas P, Montgomery RB, Wright JL, Haffner MC, Vakar-Lopez F, Mian OY, Lam HM, Hsieh AC, Ha G. Evolution and heterogeneity of lethal metastatic bladder cancer subtypes. Nature. 2026. PMID: 42749807

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH. Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urologic oncology. 2026. PMID: 42731937

Scotté F, Lustberg M, Aapro M, Ben Abid F, Bošnjak S, Ruhlmann CH, Klastersky J, Mayeur D, Rugo HS, Cooksley T. Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review. European journal of cancer (Oxford, England : 1990). 2026. PMID: 42790204

Cheng Y, Banavar A, Ma K, Obwoya PS, Luhuti K, Tuhumwire C, Gheshlaghi S, Fan K, Yang Y, Hsieh K, Hasnain AC, Ahmed Y, Ngamruenghphong S, Khashab M, Singh V, Hamilton JP, Shin EJ, Akarapipad P, Mushi B, Selekwa M, Mmbage E, Ringo Y, Tumuhimbise C, Tusiime F, Van Loon K, Byaruhanga E, Wang TH, Okello S, Buckle G, Meltzer SJ. International case-control study of DNA methylation biomarkers for the minimally invasive diagnosis of esophageal squamous cell carcinoma. Clinical and translational gastroenterology. 2026. PMID: 42727930

Shah NJ, Ravilla R, Osterland AJ, Todoroff K, Wang CY, Rane P, Saal H, Conkling PR, Wang D, Motzer RJ. Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023). The oncologist. 2026. PMID: 42742451

Perales MA, Dietrich J, Gust J, Santomasso B, Rejeski K, Hansen D, Shah NN, Berdeja J, Bishop M, Bleickardt E, Brudno J, Dahiya S, Frey N, Frigault MJ, Gardner R, Ghobadi A, Grupp S, Hamadani M, Jacobson C, Jain MD, Jain T, Komanduri KV, Kumar A, Lim S, Lin Y, Miao H, Neelapu S, Otegbeye F, Park JH, Pasquini M, Patel N, Plautz G, Verdun N, Lee DW, Maus MV, Locke FL. ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. Transplantation and cellular therapy. 2026. PMID: 42711241

Truong AA, Ho S, Lee RH, Wu X, Kang H, El-Sayed IH, George JR, Heaton CM, Likhterov I, Xu MJ, Ha PK, Algazi AP, Wai KC. Statin Use Is Associated With Progression-Free Survival for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab. Head & neck. 2026. PMID: 42712089

Iihara H, Bianchini G, Aapro M, Licata L, Bernareggi A, Navari RM, Park YH, Jordan K, Vidal M, Scotté F, Roeland EJ, Schwartzberg L, Rugo HS. Netupitant versus aprepitant: model-predicted neurokinin-1 receptor occupancy and implications for long-delayed nausea and vomiting prevention. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42701103

Choi C, Labriola M, Henderson N, Chu A, Hwang C, Barata PC, Cackowski FC, Broderick A, McKay RR, Bilen MA, Kilari D, Graham LS, Tripathi A, Garje R, Koshkin VS, Dorff TB, Schweizer MT, Reichert ZR, Sokolova AO, Marshall CH, Armstrong AJ. Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer. Prostate cancer and prostatic diseases. 2026. PMID: 42697914

Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerrer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial. Annals of surgical oncology. 2026. PMID: 42700336

Tseng J, Dimitroff K, Sauder CAM, Chien AJ, Ahmed KA, Allen LF, Arciero CA, Burke EE, Chandler JM, Jordan JE, Golshan M, Gutnik LA, Jaskowiak NT, Hewitt KC, Howard-McNatt M, Ito F, Kang IM, Kesmodel SB, Kuerer HM, Lee MC, Moran MS, Postlewait LM, Prionas ND, Rao R, Reyna CR, Schwer A, Taunk NK, Tchou J, Wallace AM, Li TJ, Perlmutter J, DeMichele AM, Yee D, Hylton NM, Veer LJV, Rugo HS, Symmans WF, Shatsky RA, Isaacs CJD, Yau C, Esserman LJ, Boughey JC, Mukhtar RA. Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. Annals of surgical oncology. 2026. PMID: 42693375

Lee EY, Tang W, Price JC, Kelley RK, Gordan JD, Lai JC, Fong L, Mehta N, Li M. Impact of hepatitis C viremia on overall survival and hepatic decompensation among patients with unresectable HCC receiving immunotherapy. Clinical and translational gastroenterology. 2026. PMID: 42684843

Rodriguez-Otero P, Morillo D, D'Souza A, Reece D, van de Donk N, Chari A, Dholaria B, Kortüm KM, Mateos MV, Mckay JT, Rosiñol L, Sureda A, Wäsch R, Bhutani M, Weisel KC, Bahlis NJ, Vishwamitra D, Skerget S, Bakshi KK, Guo Y, Sun W, Goldberg JD, Stephenson T, Prior TJ, Vandenberk L, Lee S, Smit MD, Verona RI, Oriol A, Krishnan A. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood advances. 2026. PMID: 42685673

Wang CX, Luxardi G, Mori H, Maverakis EM, Merleev AA, Marusina AI, Borowsky AD, Parikh M, Riess JW, Moshiri A, Bazhenova L, Gubens M, Koczywas M, Butner JD, Huang J, Kim SK, Vick LV, Sun Y, Canter RJ, Murphy WJ, Daly ME, Kelly K, Monjazeb AM. A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer. Oncoimmunology. 2026. PMID: 42684015